Squarepoint
SLN

Squarepoint’s Silence Therapeutics SLN Stock Holding History

Squarepoint’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$472K Buy
+89,469
New +$493K ﹤0.01% 3372

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Squarepoint's SLN Position: Q1 2026 in Review

Squarepoint opened a new position in Silence Therapeutics (SLN) in Q1 2026: 89,469 shares worth $472K. The stake represents ﹤0.01% of the portfolio and ranks #3372 among its holdings.

56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Squarepoint held 89,469 shares of Silence Therapeutics worth $472K as of Q1 2026.
  • Silence Therapeutics was a new Squarepoint position in Q1 2026.
  • Silence Therapeutics made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #3372 holding.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.